SCHEMBL6430006

SCHEMBL6430006

CCOC(=O)c1ccc(NC(C)=O)c(NCc2ccc(C(F)(F)F)cc2Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
RAB9A P51151 2/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 2/20 0.42
MRGPRX4 Q96LA9 1/20 0.42
MAPK1 P28482 1/20 0.41
CETP P11597 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ALOX15 P16050 1/20 0.41
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650334 0.88 ALDH1A1 (0.55) KMT2ACYP1A2RAB9AALDH1A1L3MBTL1
SCHEMBL6301593 0.88 HDAC1 (0.54) KMT2ACYP1A2RAB9AMEN1ALDH1A1
SCHEMBL6301341 0.86 KMT2A (0.48) KMT2ACYP1A2RAB9AALDH1A1L3MBTL1
SCHEMBL6301558 0.86 KMT2A (0.48) KMT2ACYP1A2RAB9AMEN1ALDH1A1
SCHEMBL6301182 0.85 KMT2A (0.47) KMT2ACYP1A2RAB9AMEN1ALDH1A1
SCHEMBL6301145 0.84 KMT2A (0.47) KMT2ACYP1A2RAB9AMEN1ALDH1A1
SCHEMBL6303883 0.83 RAB9A (0.59) KMT2ACYP1A2RAB9AALDH1A1HDAC1
SCHEMBL7657052 0.82 KMT2A (0.58) KMT2ARAB9AMEN1ALDH1A1POLB
SCHEMBL6301413 0.82 KMT2A (0.45) KMT2ACYP1A2RAB9AMEN1ALDH1A1
SCHEMBL6307818 0.79 ALOX15 (0.45) KMT2ACYP1A2RAB9AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6869950-B1 Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-03-22 US disclosed
US-20050014955-A1 Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative ASTRAZENECA AB (SE) 2005-01-20 US disclosed
CN-1135224-C Benzimidazole derivatives ����ҩƷ��ҵ��ʽ���� 2004-01-21 CN disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1142880-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
CN-1268123-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2000-09-27 CN disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014955-A1 Process for the preapartion 3-aryl-2-hydroxypropionic acid derivative GRHPR, PAH, P4HA1 KMT2A 2044/4885CYP1A2 15/4885CYP2C9 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.